cancer, drug development

Advanced genomic tools have provided biotech companies new approaches to help our furry friends—but experts say several limitations remain.

A study finds that engineered exosomes are effective in mice, but their potential use in humans raises safety questions.  

The binding of histamine with one of its receptors within the tumor environment makes cancer cells more resistant to immunotherapy, according to a new study. Blocking that binding could improve responses to treatment.

Tracking human cancers in mice shows some unexpected cell changes that could undermine translational research.  

A newly developed platform may one day replace cell culture and animal models to personalize cancer treatment.

In a retrospective analysis, a team found that an algorithm integrating the gene expression of a tumor with the radiation dose a patient received predicted how well the patient responded to the treatment.

An unusual drug screen takes advantage of “porcupine-like” structures of cancer cells in 3D organoids.

An unfolded protein found in human milk shows promise in early clinical trials to treat bladder cancer.

A clever approach to modifying already existing cancer therapies may be a game changer for treating metastatic breast cancer.

Clinical trials were halted after the treatment’s vector that ferries in the healthy genetic sequence was identified in the genome of a patient’s cancer cells.

Strategies to trick, manipulate, and direct the evolution of tumors

Researchers are engineering microbes to deliver therapeutics specifically to tumors, maximizing the treatments’ efficacy while minimizing side effects.

Autonomous, living microrobots that seek and destroy cancer are not as futuristic as one might imagine, thanks to a fusion of robotics and synthetic biology.

New therapeutic approaches in oncology aim to manipulate or block cancer’s adaptation to treatment.

A study of 11 drugs now in clinical trials suggests they do kill cancer cells—but through a different mechanism than indicated in previous research.

Breast cancer researcher and oncologist Nancy Davidson discusses what we’ve learned from the first wave of epigenetic trials for breast cancer, and what challenges lie ahead before such therapies reach the clinic.

Renewed interest from the biotech industry sparks hope for drugging the nucleic acid to treat cancer and other conditions.

A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.